Specific use-results survey to evaluate the safety and outcome of Pivlaz use in patients after aneurysmal subarachnoid hemorrhage treatment

Specific use-results survey to evaluate the safety and outcome of Pivlaz use in patients after aneurysmal subarachnoid hemorrhage treatment - Specific use-results survey to evaluate the safety and outcome of Pivlaz use in patients after aneurysmal subarachnoid hemorrhage treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048297

Enrollment

2000

Registered

2022-07-06

Start date

2022-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients after subarachnoid hemorrhage due to cerebral aneurysm to which this drug was administered

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety -Adverse events (AE) -Adverse drug reactions (ADR)	—

Secondary

Measure	Time frame
Outcome Evaluate the Mortality/morbidity events -Death -New cerebral vasospasm -New cerebral vasospasm-related new cerebral infarction -New cerebral vasospasm-related delayed ischemic neurological deficit (DIND) Evaluation of prognosis -mRS -GOSE -MMSE-J	—

Countries

Japan

Contacts

Public ContactRyoko Suzuki

Nxera Pharma Japan Co., Ltd. Drug Safety, PMS

ryoko.suzuki@nxera.life03-5962-5718

Outcome results